Remitting neuropsychiatric symptoms in COVID-19 patients: Viral cause or drug effect?
J Med Virol
; 94(3): 1154-1161, 2022 03.
Article
en En
| MEDLINE
| ID: mdl-34755347
ABSTRACT
Numerous reports of neuropsychiatric symptoms highlighted the pathologic potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its relationship the onset and/or exacerbation of mental disease. However, coronavirus disease 2019 (COVID-19) treatments, themselves, must be considered as potential catalysts for new-onset neuropsychiatric symptoms in COVID-19 patients. To date, immediate and long-term neuropsychiatric complications following SARS-CoV-2 infection are currently unknown. Here we report on five patients with SARS-CoV-2 infection with possible associated neuropsychiatric involvement, following them clinically until resolution of their symptoms. We will also discuss the contributory roles of chloroquine and dexamethasone in these neuropsychiatric presentations.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
COVID-19
/
Tratamiento Farmacológico de COVID-19
/
Trastornos Mentales
Tipo de estudio:
Diagnostic_studies
Idioma:
En
Revista:
J Med Virol
Año:
2022
Tipo del documento:
Article